Artiva Biotherapeutics (ARTV) Stock Price, News & Analysis

Company Overview

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s platform is designed to produce off-the-shelf NK cell treatments that can be manufactured at scale and administered without requiring cells to be collected from each individual patient.

Artiva’s lead product candidate, AlloNK, also known as AB-101, is an investigational allogeneic NK cell therapy intended to target and eliminate antibody-coated cells. The company is evaluating AlloNK in combination with antibody treatments, including rituximab, in clinical studies for conditions such as B-cell malignancies and autoimmune diseases. Its research has included applications involving B-cell depletion, an approach being investigated for diseases in which abnormal or overactive B cells contribute to illness.

Headquartered in San Diego, California, Artiva was founded to advance scalable NK cell manufacturing and cell-based immunotherapies. The company’s programs remain investigational and are being developed through clinical research and collaborations. Artiva’s shares trade on the Nasdaq under the symbol ARTV.

Key Stats

• Today's Range: $6.92 to $7.18
• 50-Day Range: $6.99 to $11.94
• 52-Week Range: $2.71 to $14.53
• Volume: 450,549 shs
• Average Volume: 463,323 shs
• Market Capitalization: $343.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $39.00
• Consensus Rating: Moderate Buy

Artiva Biotherapeutics Stock Analysis - MarketRank™

Artiva Biotherapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 456th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Artiva Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Artiva Biotherapeutics has a consensus price target of $39.00, representing about 454.8% upside from its current price of $7.03.

Amount of Analyst Coverage

Artiva Biotherapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Artiva Biotherapeutics are expected to decrease in the coming year, from ($2.62) to ($2.79) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Artiva Biotherapeutics is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Artiva Biotherapeutics is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Artiva Biotherapeutics has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.30% of the float of Artiva Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Artiva Biotherapeutics has a short interest ratio ("days to cover") of 6.65.

Change versus previous month

Short interest in Artiva Biotherapeutics has recently increased by 12.47%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Artiva Biotherapeutics does not currently pay a dividend.

Dividend Growth

Artiva Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.46

News Sentiment

Artiva Biotherapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Artiva Biotherapeutics this week, compared to 4 articles on an average week.

Search Interest

6 people have searched for ARTV on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.

MarketBeat Follows

4 people have added Artiva Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $3,286,118.00 in company stock, which represents 0.9561% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Artiva Biotherapeutics insiders have bought 913.47% more of their company's stock than they have sold. Specifically, they have bought $3,645,857.00 in company stock and sold $359,739.00 in company stock.

Percentage Held by Insiders

1.80% of the stock of Artiva Biotherapeutics is held by insiders.

Percentage Held by Institutions

Artiva Biotherapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/29/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ARTV
• Previous Symbol: NASDAQ:ARTV
• CIK: 1817241
• Web: www.artivabio.com
• Phone: (858) 267-4467
• Fax: N/A
• Employees: 115
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Artiva Biotherapeutics: $39.00
• High Price Target: $41.00
• Low Price Target: $35.00
• Potential Upside/Downside: +454.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$83.86 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -53.86%
• Return on Assets: -48.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 24.16
• Quick Ratio: 24.16

Sales & Book Value

• Annual Sales: $250 thousand
• Price / Sales: 1,374.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.48 per share
• Price / Book: 1.57

Miscellaneous

• Outstanding Shares: 48,890,000
• Free Float: 48,010,000
• Market Cap: $343.70 million
• Optionable: N/A
• Beta: 2.18